Literature DB >> 16399208

Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage.

Fabrizio Facchinetti1, Cristina Fasolato, Elda Del Giudice, Andrea Burgo, Sara Furegato, Mariella Fusco, Elisa Basso, Roberta Seraglia, Antonello D'Arrigo, Alberta Leon.   

Abstract

Several lines of evidence indicate that perturbed cellular Ca2+ homeostasis may play a prominent role in synaptic dysfunction and neuronal death in Alzheimer's disease (AD), suggesting a potential benefit of drugs capable to stabilize Ca2+ homeostasis. We here investigated the effects of a panel of L-type Ca2+ channel antagonists on the secretion of the amyloid beta-peptide (Abeta), which abnormally accumulates in the senile plaques of the brain of AD patients. We found that, in primary and immortalized neuronal cells in culture, nimodipine robustly stimulated secretion (up to about four-fold at 30 microM) of the highly amyloidogenic 42-residue isoform of Abeta (Abeta42), while leaving largely unaffected total Abeta secretion. An analogous effect was also observed in vivo, as the administration of a single dose of nimodipine (10 mg/kg i.p.) induced a significant rise of Abeta42 levels in plasma of Tg2576 mice. The effect of nimodipine was independent of blockage of L-type Ca2+ channels and capacitative calcium entry. Accordingly, nimodipine effect was largely Ca2+-independent, as neither depletion nor rise of extracellular Ca2+ abolished it. Hence, by showing that the effect of nimodipine on Abeta42 production is distinct from its ability to block Ca2+-influx pathways, we provide evidence for a previously uncharacterized effect of this long known molecule also used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399208     DOI: 10.1016/j.neurobiolaging.2005.02.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  8 in total

1.  L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease.

Authors:  Thimmappa S Anekonda; Joseph F Quinn; Christopher Harris; Kate Frahler; Teri L Wadsworth; Randall L Woltjer
Journal:  Neurobiol Dis       Date:  2010-09-09       Impact factor: 5.996

Review 2.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

3.  Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.

Authors:  Thomas Kukar; Todd E Golde
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

4.  Nimodipine promotes neurite outgrowth and protects against neurotoxicity in PC12 cells.

Authors:  Miduki Kusakabe; Yasushi Hasegawa
Journal:  Iran J Basic Med Sci       Date:  2021-01       Impact factor: 2.699

5.  The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.

Authors:  Mauro Cataldi
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

6.  A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug.

Authors:  Philip F Copenhaver; Thimmappa S Anekonda; Derek Musashe; Kristine M Robinson; Jenna M Ramaker; Tracy L Swanson; Teri L Wadsworth; Doris Kretzschmar; Randall L Woltjer; Joseph F Quinn
Journal:  Dis Model Mech       Date:  2011-05-19       Impact factor: 5.758

Review 7.  Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders.

Authors:  Sarah C Hopp
Journal:  J Neurosci Res       Date:  2020-01-29       Impact factor: 4.433

Review 8.  Presenilin-2 and Calcium Handling: Molecules, Organelles, Cells and Brain Networks.

Authors:  Paola Pizzo; Emy Basso; Riccardo Filadi; Elisa Greotti; Alessandro Leparulo; Diana Pendin; Nelly Redolfi; Michela Rossini; Nicola Vajente; Tullio Pozzan; Cristina Fasolato
Journal:  Cells       Date:  2020-09-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.